Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 mg","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foresee Pharmaceuticals Announces NDA for CAMCEVI\u2122 42MG Accepted for Review by the FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"GenScience Pharmaceuticals","pharmaFlowCategory":"D","amount":"$124.0 million","upfrontCash":"$8.0 million","newsHeadline":"Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$47.0 million","upfrontCash":"Undisclosed","newsHeadline":"Foresee Pharmaceuticals Announces Completion of US$47 Million Financing","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2\/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"TRPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Accord healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Accord BioPharma, in Partnership with Foresee Pharmaceuticals, Launches CAMCEVI\u2122 (Leuprolide) Injection Emulsion in the U.S. for the Treatment of Advanced Prostate Cancer in Adults","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$42.3 million","upfrontCash":"Undisclosed","newsHeadline":"Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion, 42 mg for the Treatment of Central Precocious Puberty Patients","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion for the Treatment of Central Precocious Puberty","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Foresee Pharmaceuticals

    Menu

    Foresee Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Foresee Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion for t...

              Details:

              FP-001 (leuprolide mesylate), which is a Gonadotropin-releasing hormone receptor agonist. Currently, it is being evaluated in Phase III clinical trial studies with patients related to Central Precocious Puberty.

              Lead Product(s): Leuprolide Mesylate

              Therapeutic Area: Endocrinology Product Name: FP-001

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 01, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Foresee Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion, 42 mg for the Treatment of Central...

              Details:

              FP-001 (leuprolide), a gonadotropin-releasing hormone (GnRH) agonist, is being developed for for the treatment of Central Precocious Puberty patients.

              Lead Product(s): Leuprolide Mesylate

              Therapeutic Area: Endocrinology Product Name: FP-001

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Foresee Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing

              Details:

              The proceeds will be used to develop Camcevi, a leuprolide mesylate injection, in a Phase 3 trial for central precocious puberty, FP-045, an ALDH2 activator, in a Phase 1b/2 trial for Fanconi Anemia, and FP-025, an MMP-12 inhibitor, in a Phase 2 study for respiratory disease.

              Lead Product(s): Leuprolide Mesylate

              Therapeutic Area: Endocrinology Product Name: Camcevi

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $42.3 million Upfront Cash: Undisclosed

              Deal Type: Financing June 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Foresee Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Accord BioPharma, in Partnership with Foresee Pharmaceuticals, Launches CAMCEVI™ (Leuprolide) Injection Emulsion in the U.S. for the Treatment of Advanced Prostate Cancer...

              Details:

              Through this partnership with Foresee on the launch of CAMCEVI, Accord BioPharma with razor sharp focus on specialty pharmaceuticals, which will go beyond biology to bring more access to high-quality medicines to patients across the U.S.

              Lead Product(s): Leuprolide Acetate

              Therapeutic Area: Oncology Product Name: Camcevi

              Highest Development Status: Approved Product Type: Peptide

              Recipient: Accord healthcare

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership April 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Foresee Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement

              Details:

              Under the terms of this partnership, Foresee and TRPharm will collaborate to initially expedite the development of FP-045 in Fanconi Anemia. Turkey and the surrounding region has a high prevalence Fanconi Anemia as well as other rare diseases.

              Lead Product(s): FP-045

              Therapeutic Area: Rare Diseases and Disorders Product Name: FP-045

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: TRPharm

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration February 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Foresee Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS

              Details:

              The randomised, double-blind, placebo-controlled, multi-centre study will assess the efficacy and safety of the highly selective FP-025. The subjects will be randomised in 1:1:1 ratio to receive FP-025 100mg or 300mg or placebo twice daily for 28 days.

              Lead Product(s): FP-025

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: FP-025

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 28, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Foresee Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Foresee Pharmaceuticals Announces Completion of US$47 Million Financing

              Details:

              The proceeds of the Public Offering will be used for supporting Foresee’s existing drug research and development programs – such as FP-025, for which a Phase II/III clinical trial IND application was recently submitted to the FDA for the treatment of ARDS in COVID-19 patients.

              Lead Product(s): FP-025

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: FP-025

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $47.0 million Upfront Cash: Undisclosed

              Deal Type: Financing December 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Foresee Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi in China

              Details:

              GenScience Pharmaceuticals will get license for the commercialization of Foresee’s novel FP-001 program, Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use subcutaneous 6-month and 3-month depot formulations. The license agreement will cover the China market.

              Lead Product(s): Leuprolide Mesylate

              Therapeutic Area: Oncology Product Name: Camcevi

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: GenScience Pharmaceuticals

              Deal Size: $124.0 million Upfront Cash: $8.0 million

              Deal Type: Licensing Agreement November 17, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Foresee Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Foresee Pharmaceuticals Announces NDA for CAMCEVI™ 42MG Accepted for Review by the FDA

              Details:

              FDA, in its Day-74 letter, stated that the New Drug Application (NDA) for CAMCEVI 42MG is sufficiently complete to permit a substantive review.

              Lead Product(s): Leuprolide Mesylate

              Therapeutic Area: Oncology Product Name: Camcevi

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Foresee Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Foresee Pharmaceuticals Announces Submission of NDA for FDA Approval of LMIS 50 mg

              Details:

              This NDA submission is supported by a previously communicated successful Phase 3 study in 137 Advanced Prostate Carcinoma patients, where treatment with LMIS 50 mg injection every 6 months was demonstrated to be effective, safe and well tolerated.

              Lead Product(s): Leuprolide Mesylate

              Therapeutic Area: Oncology Product Name: Camcevi

              Highest Development Status: Phase III Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY